Results 261 to 270 of about 352,762 (346)

Enhanced Detection of Multiple Myeloma Cells by Next‐Generation Flow Cytometry Following Density Gradient Medium Separation

European Journal of Haematology, EarlyView.
ABSTRACT Introduction Following treatment, relapse of Multiple Myeloma (MM) occurs due to measurable residual disease (MRD). As therapeutic options expand, advances in response assessment become more critical, necessitating more sensitive MRD detection methods.
Aisling O'Brien, Vitaliy Mykytiv, Fiona O'Halloran   +2 more
wiley   +1 more source

RPL29 as a radiotherapy-sensitive prognostic biomarker in multiple myeloma. [PDF]

World J Surg Oncol
Wang Y, Jia Q, Liu H, Li Z, Ma Y.
europepmc   +1 more source

Real-world outcomes for anti-CD38 monoclonal antibody-naive and exposed patients receiving treatment for multiple myeloma [PDF]

Benjamin A. Derman, Mark Watson, Jacob Ambrose, Christina M. Zettler, Andrew J. Belli, Laura L. Fernandes, Ming He   +6 more
openalex   +1 more source

Comparative Effectiveness and Safety of PI‐Rd Triplets in Relapsed/Refractory Multiple Myeloma: INSIGHT‐MM Data Analysis

European Journal of Haematology, EarlyView.
Assessment of the comparative effectiveness and safety of three PI‐Rd triplets in relapsed/refractory multiple myeloma using data from the global, non‐interventional, observational INSIGHT‐MM study. ABSTRACT Objectives To assess the effectiveness/safety of three proteasome inhibitors (PIs), plus lenalidomide‐dexamethasone (Rd) triplet regimens, for the
Noemi Puig, Xavier Leleu, Hans C. Lee, Faith E. Davies, Roman Hájek, Vania Hungria, Michael A. Thompson, Gordon Cook, Jorge Vela Ojeda, Katja C. Weisel, Jesus G. Berdeja, Saad Z. Usmani, Argiris Symeonidis, Isabel Nascimento‐Ferreira, David Arthur, Lenka Mokrá, Kaili Ren, Dasha Cherepanov, Evangelos Terpos   +18 more
wiley   +1 more source

Characterization of cytogenetic abnormalities in Lebanese multiple myeloma patients. [PDF]

BMC Cancer
Najem G, Kharsa C, Kourie HR, Kattan J, Nasr F, El Karak F, Wakim J, Ghosn M, Chahine G, Hanna C, El Ferkh R, Farra C, Chebly A.   +12 more
europepmc   +1 more source

The multiple myeloma–associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity

, 2007
Josh Lauring, Abde M. Abukhdeir, Hiroyuki Konishi, Joseph P. Garay, John P. Gustin, Qiuju Wang, R.J. Arceci, William Matsui, Ben Ho Park   +8 more
openalex   +1 more source

Factors Affecting Immune Reconstitution Post‐Allogeneic HSCT in Children: The Case for an Individualized Approach to Vaccination

European Journal of Haematology, EarlyView.
ABSTRACT Allogeneic hematopoietic stem cell transplantation (HSCT) is increasingly used to treat malignant and non‐malignant diseases. Following allogeneic HSCT, patients are particularly vulnerable to vaccine‐preventable diseases (VPD) because conditioning depletes immune cells, including memory cells.
Hélène Buvelot, Frederic Baleydier, Laure Pittet, Geraldine Blanchard‐Rohner   +3 more
wiley   +1 more source

T Cells Dysfunction in Multiple Myeloma. [PDF]

Immunotargets Ther
Cai L, Zuo L, Wang G, Li Q, Ma C, Wu J, Sun C, Hu Y.   +7 more
europepmc   +1 more source

Survival and Renal Recovery in Newly Diagnosed Multiple Myeloma Patients Presenting With Dialysis‐Requiring Severe Renal Impairment

European Journal of Haematology, EarlyView.
ABSTRACT Background Severe renal insufficiency requiring dialysis in newly diagnosed multiple myeloma (NDMM) patients has been independently associated with poor survival outcomes. However, there is a paucity of data on factors predicting renal recovery and survival outcomes of these patients.
Rintu Sharma, Eshetu G. Atenafu, Esther Masih‐Khan, Harjot Vohra, Sita Bhella, Christine Chen, Vishal Kukreti, Guido Lancman, Anca Prica, A. Keith Stewart, Rodger Tiedemann, Suzanne Trudel, Chloe Yang, Donna Reece   +13 more
wiley   +1 more source

Identification of Potential Ferroptosis Biomarkers in Multiple Myeloma via WGCNA and Experiments. [PDF]

Cancer Rep (Hoboken)
Wang Y, Xie X, Gu M, Zheng Y, Wu J, Wang Q, Ling Z, Li R.   +7 more
europepmc   +1 more source